IONSIonis Pharmaceuticals, Inc.Running, no new patients
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
Amyotrophic Lateral Sclerosis
8Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +7.8
2 insiders sold shares within a month
Since Oct 16, 2026 · was worth 10, fading over time
Worry score8
Score over time
- Stage
- Phase 3
- Patients
- 89 (final count)
- Started
- Jun 14, 2021
- Main results expected
- Jun 17, 2026
- Fully finished
- Mar 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Change from Baseline (Day 1) through Study Day 505 in Part 1 in functional impairment
Measured over: Baseline, Day 505 in Part 1
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 7.8, since 2026-10-16, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04768972 · record last updated 2026-07-21 · checked 2026-11-09 15:47 UTC